1. Home
  2. SPFI vs ACRS Comparison

SPFI vs ACRS Comparison

Compare SPFI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo South Plains Financial Inc.

SPFI

South Plains Financial Inc.

HOLD

Current Price

$41.75

Market Cap

812.0M

Sector

Finance

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.26

Market Cap

868.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPFI
ACRS
Founded
1941
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
812.0M
868.5M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
SPFI
ACRS
Price
$41.75
$5.26
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
★ $46.00
$10.20
AVG Volume (30 Days)
93.2K
★ 2.4M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
★ 1.68%
N/A
EPS Growth
17.81
★ 69.01
EPS
★ 1.82
N/A
Revenue
N/A
★ $1,683,000.00
Revenue This Year
$22.65
N/A
Revenue Next Year
$9.40
$4.24
P/E Ratio
$22.87
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.34
$1.74
52 Week High
$46.94
$6.60

Technical Indicators

Market Signals
Indicator
SPFI
ACRS
Relative Strength Index (RSI) 27.98 41.16
Support Level $41.24 $4.99
Resistance Level $42.58 $5.83
Average True Range (ATR) 0.85 0.35
MACD -0.27 -0.04
Stochastic Oscillator 3.50 24.68

Price Performance

Historical Comparison
SPFI
ACRS

About SPFI South Plains Financial Inc.

South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: